Clinical Trial

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Study acronym: V-INTERVENTION
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.
Protocol Amendment History 7 changes
notable Trial sites expanded: 115 -> 125 locations 2026-08-06
notable Trial sites expanded: 112 -> 115 locations 2026-07-24
notable Trial sites expanded: 103 -> 107 locations 2026-07-02
notable Trial sites expanded: 99 -> 102 locations 2026-06-11
notable Trial sites expanded: 96 -> 100 locations 2026-06-02
notable Trial sites expanded: 78 -> 96 locations 2026-05-13
notable Trial sites expanded: 71 -> 78 locations 2026-04-07
Trial Details
NCT Number NCT06909565
Lead Sponsor Duke University
Collaborators: Novartis Pharmaceuticals, Colorado Prevention Center, Mount Sinai Hospital, New York
Conditions Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Enrollment 6,000 participants
Start Date 2025-07-23
Primary Completion 2029-10 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-05